📢 Gate Square Exclusive: #PUBLIC Creative Contest# Is Now Live!
Join Gate Launchpool Round 297 — PublicAI (PUBLIC) and share your post on Gate Square for a chance to win from a 4,000 $PUBLIC prize pool
🎨 Event Period
Aug 18, 2025, 10:00 – Aug 22, 2025, 16:00 (UTC)
📌 How to Participate
Post original content on Gate Square related to PublicAI (PUBLIC) or the ongoing Launchpool event
Content must be at least 100 words (analysis, tutorials, creative graphics, reviews, etc.)
Add hashtag: #PUBLIC Creative Contest#
Include screenshots of your Launchpool participation (e.g., staking record, reward
BeiGene: MCLA-129 is currently exploring indications in the field of lung cancer.
Jin10 data reported on August 19, Beida Pharmaceutical stated on the interactive platform that MCLA-129 is a bispecific antibody targeting both EGFR and c-Met, currently exploring indications in the field of lung cancer. A recent Phase II study related to driver gene positivity and MET amplification has completed the enrollment of its first patient. The company will disclose any significant research progress in a timely manner.